{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:42:08Z","timestamp":1792460528498,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The importance of MCL-1 in leukemogenesis has prompted development of MCL-1 antagonists e.g., S63845, MIK665. However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via the ubiquitin proteasome system. Here, we investigated mechanisms by which kinase inhibitors with Src inhibitory activity e.g., bosutinib (SKI-606) might circumvent this phenomenon. MCL-1 antagonist\/SKI-606 co-administration synergistically induced apoptosis in diverse AML cell lines. Consistently, Src or MCL-1 knockdown with shRNA markedly sensitized cells to MCL-1 inhibitors or SKI-606 respectively, while ectopic MCL-1 expression significantly diminished apoptosis. Mechanistically, MCL-1 antagonist exposure induced MCL-1 up-regulation, an event blocked by Src inhibitors or Src shRNA knock-down. MCL-1 down-regulation was associated with diminished transcription and increased K48-linked degradative ubiquitination. Enhanced cell death depended functionally upon down-regulation of phosphorylated STAT3 (Tyr705\/Ser727) and cytoprotective downstream targets c-Myc and BCL-xL, as well as BAX\/BAK activation, and NOXA induction. Importantly, the Src\/MCL-1 inhibitor regimen robustly killed primary AML cells, including primitive progenitors, but spared normal hematopoietic CD34<jats:sup>+<\/jats:sup> cells and human cardiomyocytes. Notably, the regimen significantly improved survival in an MV4-11 cell xenograft model, while reducing tumor burden in two patient-derived xenograft (PDX) AML models and increased survival in a third. These findings argue that Src inhibitors such as SKI-606 potentiate MCL-1 antagonist anti-leukemic activity in vitro and in vivo by blocking MCL-1 antagonist-mediated cytoprotective MCL-1 accumulation by promoting degradative ubiquitination, disrupting STAT-3-mediated transcription, and inducing NOXA-mediated MCL-1 degradation. They also suggest that this strategy may improve MCL-1 antagonist efficacy in AML and potentially other malignancies.<\/jats:p>","DOI":"10.1038\/s41392-025-02125-x","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T23:03:56Z","timestamp":1739142236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-0896","authenticated-orcid":false,"given":"Xiaoyan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jewel","family":"Nkwocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kmieciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhe","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Ashley","family":"Cowart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hawkridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo G.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi N.","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Hazlehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Sdrimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zackary","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon D.","family":"Ginder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-9320","authenticated-orcid":false,"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2125_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja, A. et al. Acute myeloid leukaemia. Nat. Rev. Dis. Prim. 2, 16010 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2125_CR2","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B Deschler","year":"2006","unstructured":"Deschler, B. & Lubbert, M. Acute myeloid leukemia: epidemiology and etiology. Cancer 107, 2099\u20132107 (2006).","journal-title":"Cancer"},{"key":"2125_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser, S. & Levis, M. J. Updates on targeted therapies for acute myeloid leukaemia. Br. J. Haematol. 196, 316\u2013328 (2022).","journal-title":"Br. J. Haematol."},{"key":"2125_CR4","first-page":"1","volume":"15","author":"Y Li","year":"2023","unstructured":"Li, Y. & Zhou, F. Efficacy of bone marrow transplantation in treating acute myeloid leukemia: a systematic review and meta-analysis. Am. J. Transl. Res 15, 1\u201312 (2023).","journal-title":"Am. J. Transl. Res"},{"key":"2125_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu, H. Emerging agents and regimens for AML. J. Hematol. Oncol. 14, 49 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2125_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts, A. W., Wei, A. H. & Huang, D. C. S. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood 138, 1120\u20131136 (2021).","journal-title":"Blood"},{"key":"2125_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.molcel.2020.05.014","volume":"78","author":"A Strasser","year":"2020","unstructured":"Strasser, A. & Vaux, D. L. Cell death in the origin and treatment of cancer. Mol. Cell. 78, 1045\u20131054 (2020).","journal-title":"Mol. Cell."},{"key":"2125_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl, M. et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 5, 1552\u20131564 (2021).","journal-title":"Blood Adv."},{"key":"2125_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2125_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct. Target Ther. 7, 51 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2125_CR11","doi-asserted-by":"publisher","first-page":"18407","DOI":"10.1074\/jbc.M610010200","volume":"282","author":"S Kobayashi","year":"2007","unstructured":"Kobayashi, S. et al. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J. Biol. Chem. 282, 18407\u201318417 (2007).","journal-title":"J. Biol. Chem."},{"key":"2125_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser, S. P. et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26, 120\u2013125 (2012).","journal-title":"Genes Dev."},{"key":"2125_CR13","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","volume":"99","author":"B Zhang","year":"2002","unstructured":"Zhang, B., Gojo, I. & Fenton, R. G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99, 1885\u20131893 (2002).","journal-title":"Blood"},{"key":"2125_CR14","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41388-019-1122-x","volume":"39","author":"MA Dengler","year":"2020","unstructured":"Dengler, M. A. et al. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene 39, 2009\u20132023 (2020).","journal-title":"Oncogene"},{"key":"2125_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18372-1","volume":"11","author":"E Munkhbaatar","year":"2020","unstructured":"Munkhbaatar, E. et al. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat. Commun. 11, 4527 (2020).","journal-title":"Nat. Commun."},{"key":"2125_CR16","doi-asserted-by":"crossref","unstructured":"Merino, D. et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci. Transl. Med. 9 (2017).","DOI":"10.1126\/scitranslmed.aam7049"},{"key":"2125_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/onc.2016.247","volume":"36","author":"J Tong","year":"2017","unstructured":"Tong, J., Tan, S., Zou, F., Yu, J. & Zhang, L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene 36, 787\u2013796 (2017).","journal-title":"Oncogene"},{"key":"2125_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang, H., Guo, M., Wei, H. & Chen, Y. Targeting MCL-1 in cancer: current status and perspectives. J. Hematol. Oncol. 14, 67 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2125_CR19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey, H. E. et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8, 1566\u20131581 (2018).","journal-title":"Cancer Discov."},{"key":"2125_CR20","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2007-04-082099","volume":"111","author":"C Dos Santos","year":"2008","unstructured":"Dos Santos, C. et al. A critical role for Lyn in acute myeloid leukemia. Blood 111, 2269\u20132279 (2008).","journal-title":"Blood"},{"key":"2125_CR21","doi-asserted-by":"publisher","first-page":"e0225887","DOI":"10.1371\/journal.pone.0225887","volume":"14","author":"RK Patel","year":"2019","unstructured":"Patel, R. K. et al. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance. PLoS ONE 14, e0225887 (2019).","journal-title":"PLoS ONE"},{"key":"2125_CR22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.bcp.2011.05.011","volume":"82","author":"E Lainey","year":"2011","unstructured":"Lainey, E. et al. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. Biochem. Pharm. 82, 1457\u20131466 (2011).","journal-title":"Biochem. Pharm."},{"key":"2125_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garcia-Gutierrez","year":"2019","unstructured":"Garcia-Gutierrez, V. & Hernandez-Boluda, J. C. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 9, 603 (2019).","journal-title":"Front Oncol."},{"key":"2125_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.leukres.2007.11.032","volume":"32","author":"Y Ozawa","year":"2008","unstructured":"Ozawa, Y. et al. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk. Res. 32, 893\u2013903 (2008).","journal-title":"Leuk. Res."},{"key":"2125_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1541-7786.MCR-16-0212","volume":"15","author":"P Abdollahi","year":"2017","unstructured":"Abdollahi, P. et al. Src family kinases are regulated in multiple myeloma cells by phosphatase of regenerating liver-3. Mol. Cancer Res. 15, 69\u201377 (2017).","journal-title":"Mol. Cancer Res."},{"key":"2125_CR26","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner, K. V. et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 118, 1885\u20131898 (2011).","journal-title":"Blood"},{"key":"2125_CR27","doi-asserted-by":"publisher","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","volume":"8","author":"JT Leonard","year":"2016","unstructured":"Leonard, J. T. et al. Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci. Transl. Med. 8, 354ra114 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2125_CR28","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/blood-2006-09-045039","volume":"109","author":"TK Nguyen","year":"2007","unstructured":"Nguyen, T. K., Rahmani, M., Harada, H., Dent, P. & Grant, S. MEK1\/2 inhibitors sensitize Bcr\/Abl+ human leukemia cells to the dual Abl\/Src inhibitor BMS-354\/825. Blood 109, 4006\u20134015 (2007).","journal-title":"Blood"},{"key":"2125_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0165-5","volume":"9","author":"W Fiskus","year":"2019","unstructured":"Fiskus, W. et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 9, 4 (2019).","journal-title":"Blood Cancer J."},{"key":"2125_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1078-0432.CCR-22-2088","volume":"29","author":"SI Tantawy","year":"2023","unstructured":"Tantawy, S. I. et al. Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-cell malignancies. Clin. Cancer Res 29, 446\u2013457 (2023).","journal-title":"Clin. Cancer Res"},{"key":"2125_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0781-6","volume":"18","author":"AI Young","year":"2016","unstructured":"Young, A. I. et al. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Res. 18, 125 (2016).","journal-title":"Breast Cancer Res."},{"key":"2125_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1126\/science.7541555","volume":"269","author":"CL Yu","year":"1995","unstructured":"Yu, C. L. et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81\u201383 (1995).","journal-title":"Science"},{"key":"2125_CR33","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1038\/sj.onc.1205859","volume":"21","author":"G Niu","year":"2002","unstructured":"Niu, G. et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21, 7001\u20137010 (2002).","journal-title":"Oncogene"},{"key":"2125_CR34","doi-asserted-by":"publisher","first-page":"7356","DOI":"10.1002\/jcp.30407","volume":"236","author":"JT Chiou","year":"2021","unstructured":"Chiou, J. T. et al. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. J. Cell Physiol. 236, 7356\u20137375 (2021).","journal-title":"J. Cell Physiol."},{"key":"2125_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-016-0292-z","volume":"9","author":"A Al-Mawali","year":"2016","unstructured":"Al-Mawali, A., Gillis, D. & Lewis, I. Immunoprofiling of leukemic stem cells CD34+\/CD38-\/CD123+ delineate FLT3\/ITD-positive clones. J. Hematol. Oncol. 9, 61 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2125_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101015","volume":"23","author":"ML Rasmussen","year":"2020","unstructured":"Rasmussen, M. L. et al. MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience 23, 101015 (2020).","journal-title":"iScience"},{"key":"2125_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fphar.2018.00084","volume":"9","author":"X Zhu","year":"2018","unstructured":"Zhu, X., Shen, X., Qu, J., Straubinger, R. M. & Jusko, W. J. Proteomic analysis of combined gemcitabine and birinapant in pancreatic cancer cells. Front Pharm. 9, 84 (2018).","journal-title":"Front Pharm."},{"key":"2125_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152835","volume":"458","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Metabolomics analysis underlay mechanisms in the renal impairment of mice caused by combination of aflatoxin M1 and ochratoxin A. Toxicology 458, 152835 (2021).","journal-title":"Toxicology"},{"key":"2125_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/blood-2008-06-165134","volume":"113","author":"X Deng","year":"2009","unstructured":"Deng, X., Gao, F. & May, W. S. Protein phosphatase 2A inactivates Bcl2\u2019s antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 113, 422\u2013428 (2009).","journal-title":"Blood"},{"key":"2125_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28440-3","volume":"13","author":"CS Blaha","year":"2022","unstructured":"Blaha, C. S. et al. A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis. Nat. Commun. 13, 899 (2022).","journal-title":"Nat. Commun."},{"key":"2125_CR41","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41375-023-01946-5","volume":"37","author":"G Catalano","year":"2023","unstructured":"Catalano, G. et al. MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs\u2019 patients. Leukemia 37, 1600\u20131610 (2023).","journal-title":"Leukemia"},{"key":"2125_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100672","volume":"44","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 44, 100672 (2020).","journal-title":"Blood Rev."},{"key":"2125_CR43","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","volume":"114","author":"G Yoshimoto","year":"2009","unstructured":"Yoshimoto, G. et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114, 5034\u20135043 (2009).","journal-title":"Blood"},{"key":"2125_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin, V. V., Streletskaia, A. Y., Gorbunova, A. S., Zhivotovsky, B. & Kopeina, G. S. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 27, 405\u2013419 (2020).","journal-title":"Cell Death Differ."},{"key":"2125_CR45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter, J. L. et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct. Target Ther. 5, 288 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2125_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3324\/haematol.2015.124016","volume":"100","author":"V Leoni","year":"2015","unstructured":"Leoni, V. & Biondi, A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica 100, 295\u2013299 (2015).","journal-title":"Haematologica"},{"key":"2125_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.tibs.2012.11.007","volume":"38","author":"E Rieser","year":"2013","unstructured":"Rieser, E., Cordier, S. M. & Walczak, H. Linear ubiquitination: a newly discovered regulator of cell signalling. Trends Biochem. Sci. 38, 94\u2013102 (2013).","journal-title":"Trends Biochem. Sci."},{"key":"2125_CR48","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/1541-7786.MCR-21-0366","volume":"20","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. Chk1 inhibition potently blocks STAT3 Tyrosine705 phosphorylation, DNA-binding activity, and activation of downstream targets in human multiple myeloma cells. Mol. Cancer Res. 20, 456\u2013467 (2022).","journal-title":"Mol. Cancer Res."},{"key":"2125_CR49","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s13402-023-00817-6","volume":"46","author":"L Li","year":"2023","unstructured":"Li, L. et al. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells. Cell Oncol. (Dordr.) 46, 1369\u20131380 (2023).","journal-title":"Cell Oncol. (Dordr.)"},{"key":"2125_CR50","doi-asserted-by":"crossref","unstructured":"Tesoriere, A., Dinarello, A. & Argenton, F. The roles of post-translational modifications in STAT3 biological activities and functions. Biomedicines 9 (2021).","DOI":"10.3390\/biomedicines9080956"},{"key":"2125_CR51","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-08-2944","volume":"69","author":"B Sen","year":"2009","unstructured":"Sen, B., Saigal, B., Parikh, N., Gallick, G. & Johnson, F. M. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 69, 1958\u20131965 (2009).","journal-title":"Cancer Res."},{"key":"2125_CR52","doi-asserted-by":"crossref","unstructured":"Morales-Martinez, M. & Vega, M. I. Roles and regulation of BCL-xL in hematological malignancies. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms23042193"},{"key":"2125_CR53","doi-asserted-by":"crossref","unstructured":"Tolomeo, M. & Cascio, A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int. J. Mol. Sci. 22 (2021).","DOI":"10.3390\/ijms22020603"},{"key":"2125_CR54","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","volume":"117","author":"MS Redell","year":"2011","unstructured":"Redell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B. & Tweardy, D. J. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117, 5701\u20135709 (2011).","journal-title":"Blood"},{"key":"2125_CR55","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2005-02-0734","volume":"106","author":"H Luo","year":"2005","unstructured":"Luo, H. et al. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 106, 2452\u20132461 (2005).","journal-title":"Blood"},{"key":"2125_CR56","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu, P., Nielsen, T. E. & Clausen, M. H. FDA-approved small-molecule kinase inhibitors. Trends Pharm. Sci. 36, 422\u2013439 (2015).","journal-title":"Trends Pharm. Sci."},{"key":"2125_CR57","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood-2015-06-653717","volume":"127","author":"L Zhou","year":"2016","unstructured":"Zhou, L. et al. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood 127, 2219\u20132230 (2016).","journal-title":"Blood"},{"key":"2125_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzym. Regul."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02125-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02125-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02125-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T23:04:00Z","timestamp":1739142240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02125-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2125"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02125-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal studies were performed under protocol AM10204, approved by our local IACUC, and regulated by VCU\u2019s Animal Care and Use Program, in accordance with AAALAC, USDA, and PHS guidelines, and all studies were obtained with written informed consent from all participating patients undergoing routine diagnostic aspirations, were conducted in accordance with recognized ethical guidelines (e.g., the Declaration of Helsinki), and were approved by the Virginia Commonwealth Institutional Review Board (#MCC-8712-3A; MCC-02447; MCC-03340).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"50"}}